Bromfenac can be used in the research of ocular inflammation that is a potent and orally active COX inhibitor with IC50 values of 5.56 and 7.45 nM for COX-1 and COX-2, respectively [1].

Bromfenac, at concentrations ranging from 0 to 80 μg/mL over 24 hours, inhibits the transforming growth factor-β2 (TGF-β2)-induced epithelial-mesenchymal transition (EMT) in HLEC-B3 cells in a dose-dependent manner [2]. Similarly, at a concentration of 80 μg/mL for 48 hours, it suppresses TGF-β2-induced EMT in human anterior capsules, as evidenced by cell viability assays on TGF-β2-treated human anterior capsules, and cell migration assays on HLEC-B3 cells. These assays further confirm that bromfenac effectively prevents the TGF-β2-induced cell migration and over-expression of EMT markers in primary lens epithelial cells (LECs) and HLEC-B3 cells, respectively [2].

Bromfenac demonstrates significant anti-inflammatory effects in various concentrations and application methods across animal models. In rats, concentrations as low as 0.1% with 4 hours of pretreatment and 0.32% with 18 hours of pretreatment, applied to the backs, show noteworthy anti-inflammatory activity. A similar dose-related effect is observed when applied to the rats' paws. Notably, a concentration range of 0.032-1.0% applied to guinea pigs' skin exposed to UV light reveals that Bromfenac is 26 times more potent than indomethacin in reducing erythema. Additionally, a consistent dose and time-dependent reduction in paw volume were achieved in rats with applications on the uninjected paw, demonstrating systemic effects. In the context of abdominal constriction responses to acetylcholine in mice, a 0.32% concentration applied to the abdomen effectively blocks these responses. Furthermore, Bromfenac eyedrop instillation at 0.09% concentration, administered twice daily for four weeks, modestly reduces corneal staining in a progressive manner over the treatment period. These findings underscore Bromfenac's broad potential in anti-inflammatory applications across different models and conditions.